Cellectar Biosciences, Inc.

CLRB Nasdaq SEC CIK 1279704
Follow Cellectar Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$8M −79.5% vs same quarter last year
EPS, diluted −$0.46 +67.4% vs same quarter last year
Operating cash flow −$9.4M −120.2% vs same quarter last year
Operating income −$8.1M −67.1% vs same quarter last year
Net income by quarter
−$2.4M
−$6.6M
−$5.4M
−$4.4M
−$5.3M
−$5.7M
−$6.9M
−$8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$21.8M
FY24−$44.6M
FY23−$38M
FY22−$31.8M
FY21−$24.1M
FY20−$15.1M
FY19−$14.1M
FY18−$13.2M
FY17−$13.6M
FY16−$6.2M
FY15−$5.5M
FY14−$8.1M
FY13−$10.8M
FY12−$8.8M
FY11−$7.4M
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$23.1M
FY24−$47.7M
FY23−$33.2M
FY22−$25.4M
FY21−$22.7M
FY20−$14M
FY19−$11.7M
FY18−$11.8M
FY17−$11.4M
FY16−$8.4M
FY15−$8.3M
FY14−$8.9M
FY13−$9.3M
FY12−$6.7M
FY11−$6.1M